5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
    Journal Article

    Herati, R. S.; Knorr, D. A.; Vella, L. A.; Silva, L. V.; Chilukuri, L.; Apostolidis, S. A.; Huang, A. C.; Muselman, A.; Manne, S.; Kuthuru, O.; more...
    Nature Immunology (2022)

    Fulltext@MSK | Save
  • Oligometastatic squamous cell transformation from metastatic prostate adenocarcinoma treated with systemic and focal therapy: A case report
    Journal Article

    Autio, K.; McBride, S.
    Journal of Immunotherapy and Precision Oncology (2022)

    Fulltext@MSK | Save
  • Analytical validation and performance characteristics of molecular serum biomarkers, miR-371a-3p and miR-372-3p, for male germ cell tumors, in a clinical laboratory setting
    Journal Article

    Ye, F.; Feldman, D. R.; Valentino, A.; So, R.; Bromberg, M.; Khan, S.; Funt, S. A.; Sheinfeld, J.; Solit, D. B.; Pessin, M. S.; more...
    Journal of Molecular Diagnostics (2022)

    Fulltext@MSK | Save
  • Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
    Journal Article

    Ceyhan-Birsoy, O.; Jayakumaran, G.; Kemel, Y.; Misyura, M.; Aypar, U.; Jairam, S.; Yang, C.; Li, Y.; Mehta, N.; Maio, A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • First-line systemic treatment of recurrent prostate cancer after primary or salvage local therapy: A systematic review of the literature
    Review

    Weiner, A. B.; Siebert, A. L.; Fenton, S. E.; Abida, W.; Agarwal, N.; Davis, I. D.; Dorff, T. B.; Gleave, M.; James, N. D.; Poon, D. M. C.; more...
    European Urology Oncology (2022)

    Fulltext@MSK | Save
  • The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
    Journal Article

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Nguyen, B.; Stopsack, K. H.; Kreitzer, C.; Rajanala, S. H.; Ghale, R.; Mazzu, Y. Z.; Pillarsetty, N. V. K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
    Journal Article

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S. A.; Antonescu, C. R.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N. D.; Rana, S.; Zehir, A.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
    Journal Article

    Gounder, M. M.; Agaram, N. P.; Trabucco, S. E.; Robinson, V.; Ferraro, R. A.; Millis, S. Z.; Krishnan, A.; Lee, J.; Attia, S.; Abida, W.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: Data from the phase III JAVELIN Renal 101 trial
    Journal Article

    Rini, B. I.; Moslehi, J. J.; Bonaca, M.; Schmidinger, M.; Albiges, L.; Choueiri, T. K.; Motzer, R. J.; Atkins, M. B.; Haanen, J.; Mariani, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save